These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9573653)

  • 21. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing role of carbapenems in the treatment of lower respiratory tract infections.
    Lode H; Hamacher J; Eller J; Schaberg T
    Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
    Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
    Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
    Edwards SJ; Campbell HE; Plumb JM
    Eur J Health Econ; 2006 Mar; 7(1):72-8. PubMed ID: 16429296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imipenem/cilastatin: the first carbapenem antibiotic.
    Lyon JA
    Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem: a new carbapenem antimicrobial.
    Pryka RD; Haig GM
    Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibacterial activity of biapenem against recent clinical isolates].
    Hara T; Araake M; Watabe H
    Jpn J Antibiot; 2003 Apr; 56(2):138-41. PubMed ID: 12825414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meropenem, a new carbapenem antibiotic.
    Fish DN; Singletary TJ
    Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells.
    Cornacchione P; Scaringi L; Capodicasa E; Fettucciari K; Rosati E; Sabatini R; Benedetti C; Marconi P; Rossi R; Del Favero A
    Chemotherapy; 2000; 46(2):135-42. PubMed ID: 10671765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of imipenem and meropenem on serum sensitivity and surface hydrophobicity of Klebsiella pneumoniae.
    Hostacká A
    Arzneimittelforschung; 1998 Nov; 48(11):1101-3. PubMed ID: 9850433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin.
    Böswald M; Döbig C; Kändler C; Krüger C; Scharf J; Soergel F; Zink S; Guggenbichler JP
    Infection; 1999; 27(4-5):299-304. PubMed ID: 10885853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
    Mohr JF
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA; Bryson HM; Brogden RN
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.